Piper Jaffray Companies restated their buy rating on shares of Becton, Dickinson and Company (NYSE:BDX) in a research note released on Tuesday morning. They currently have a $213.00 target price on the medical instruments supplier’s stock.

BDX has been the subject of a number of other research reports. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an outperform rating to a strong-buy rating and lowered their price target for the company from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company reaffirmed an outperform rating and issued a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub raised shares of Becton, Dickinson and from a buy rating to a strong-buy rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Becton, Dickinson and from a hold rating to a buy rating and set a $225.00 price target for the company in a report on Monday, July 17th. Finally, Bank of America Corporation reaffirmed a buy rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Becton, Dickinson and currently has an average rating of Buy and an average price target of $196.93.

Shares of Becton, Dickinson and (NYSE BDX) opened at 195.34 on Tuesday. The stock has a 50 day moving average price of $199.43 and a 200-day moving average price of $191.33. Becton, Dickinson and has a 1-year low of $161.29 and a 1-year high of $206.63. The company has a market cap of $44.45 billion, a price-to-earnings ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.35 earnings per share. Equities research analysts forecast that Becton, Dickinson and will post $9.46 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/becton-dickinson-ands-bdx-buy-rating-reiterated-at-piper-jaffray-companies.html.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s payout ratio is currently 83.43%.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. BlackRock Inc. lifted its stake in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after purchasing an additional 15,887,611 shares during the last quarter. Koch Industries Inc. lifted its stake in Becton, Dickinson and by 45,268.7% in the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after purchasing an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. lifted its stake in Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC bought a new stake in Becton, Dickinson and in the second quarter worth about $225,164,000. Finally, Janus Henderson Group PLC lifted its stake in Becton, Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after purchasing an additional 1,122,191 shares during the last quarter. 87.43% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.